Panorama prenatal test— the most comprehensive and accurate non-invasive prenatal screening test among those available at the time of the original publication. It estimates the individual risk of having a baby with chromosomal abnormalities. The method was developed through research by the American company Natera, which specializes in reproductive technologies and prenatal diagnosis. This technique began being used in the United States in 2012.
The principal difference from invasive diagnostic methods (amniocentesis, cordocentesis and chorionic villus sampling) is that no invasive procedure is required.
Only maternal venous blood is required for the analysis, so no manipulations are performed that could cause the pregnancy to end. Fetal DNA is isolated and analysed from the mother’s blood, making it possible to obtain more reliable results than with conventional biochemical screening.
Blood for Panorama testing can be collected from nine weeks of pregnancy.
The collected blood sample is separated into layers using a centrifuge. A special technique, sequencing, is then used to process genetic information from the mother and the fetus. Sequencing data are analysed by Natera's proprietary algorithm, NATUS, which helps distinguish maternal and fetal DNA. The fetal DNA information is subjected to computer analysis, and the results are used to calculate an individual risk level for chromosomal abnormalities.
Turnaround time: approximately two weeks from blood collection to receiving the test results.
The test examines chromosomes. A typical human cell contains 46 chromosomes arranged in 23 pairs.
An extra chromosome in a pair is called a trisomy; the absence of one chromosome is called a monosomy.
The non-invasive prenatal Panorama test makes it possible to determine the degree of risk of conditions such as:
Non-invasive prenatal DNA testing with Panorama may be considered in the following situations:
Panorama is a non-invasive screening method for selected chromosomal conditions. Test eligibility depends on pregnancy characteristics and medical history; consult your healthcare professional.
Benefits of Panorama NIPT
Screening from early pregnancy
From 9 weeks of pregnancy
Non-invasive for mother and fetus
- Routine venous blood draw
- A trained healthcare professional collects the sample
Convenient access from different cities
Ask our consultant about collection kits
Fast
10–14 working days
Accuracy: 99%
- Low false-positive rate
- SNP-based method distinguishes maternal and placental DNA
Fetal fraction (placental DNA proportion)
- Analysis considers maternal and placental DNA
- A sufficient fetal fraction is required for a result
Have a question?
Let us discuss it. Complete the form and our specialist will answer your questions.
We serve patients across Georgia!